Can molecular biomarker-based patient selection in Phase I trials accelerate anticancer drug development?
de Bono, JS
MetadataShow full item record
Anticancer drug development remains slow, costly and inefficient. One way of addressing this might be the use of predictive biomarkers to select patients for Phase I/II trials. Such biomarkers, which predict response to molecular-targeted agents, have the potential to enrich these trials with patients more likely to benefit. Doing so could maximize the efficiency of anticancer drug development by facilitating earlier clinical qualification of predictive biomarkers and generating valuable information on cancer biology. In this review, we suggest a new model of early clinical trial design, which incorporates patient selection through predictive molecular biomarkers for selected targeted agents.
Clinical Trials, Phase I as Topic
Clinical Pharmacology – Adaptive Therapy
Medicine Drug Development Unit (de Bono)
Prostate Cancer Targeted Therapy Group
Cell Cycle Control (including GCLP Biomarker Group)
Medicine Drug Development Unit (Kaye)
License start date
Drug discovery today, 2010, 15 (3-4), pp. 88 - 97